In This Article:
News Release
January 23, 2025
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today their publication of reference intervals using BioPorto’s NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients.
The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required step for laboratories to implement clinical tests. These findings address the critical gaps in kidney injury management and ultimately can help with earlier identification of AKI with the use of biomarkers.
This BioPorto study is the largest comprehensive study to date of 629 patients with ages ranging from three months to older than 65 years. Tabari Baker, PhD, Vice President of Global Medical Affairs states, “NGAL reference intervals in healthy populations are an essential tool for laboratory scientists and clinicians to use in patients at risk of acute kidney injury. This publication, in conjunction with our recently published GUIDANCE clinical validation trial, demonstrates BioPorto’s commitment to developing clinical tools for improving patient outcomes.”
The publication can be found here: Determination of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) Reference Intervals in Healthy Adult and Pediatric Individuals Using a Particle-Enhanced Turbidimetric Immunoassay.
To subscribe to investor news from BioPorto, please sign up at https://bioporto.com/investor-contact/
For product information visit bioporto.com or connect with a team member at https://bioporto.com/schedule-a-meeting/
For further information
Jennifer Zonderman, BioPorto, +1 617 694 2918, jmz@bioporto.com
Niels Hoy Nielsen, +45 4529 0000, investor@bioporto.com
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/.